Shaalee Dworski

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Epidermal 1-O-acylceramides appear with the establishment of the water permeability barrier in mice and are produced by maturating keratinocytes.

Epidermal 1-O-acylceramides appear with the establishment of the water permeability barrier in mice and are produced by maturating keratinocytes.

Journal: Lipids

Published: January 18, 2022

Endogenous levels of 1-O-acylceramides increase upon acidic ceramidase deficiency and decrease due to loss of Dgat1 in a tissue-dependent manner.

Endogenous levels of 1-O-acylceramides increase upon acidic ceramidase deficiency and decrease due to loss of Dgat1 in a tissue-dependent manner.

Journal: Biochimica et biophysica acta. Molecular and cell biology of lipids

Published: January 17, 2020

Chronic lung injury and impaired pulmonary function in a mouse model of acid ceramidase deficiency.

Chronic lung injury and impaired pulmonary function in a mouse model of acid ceramidase deficiency.

Journal: American journal of physiology. Lung cellular and molecular physiology

Published: November 24, 2017

Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency.

Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency.

Journal: Scientific reports

Published: September 21, 2017

Transplantation of Skin Precursor-Derived Schwann Cells Yields Better Locomotor Outcomes and Reduces Bladder Pathology in Rats with Chronic Spinal Cord Injury.

Transplantation of Skin Precursor-Derived Schwann Cells Yields Better Locomotor Outcomes and Reduces Bladder Pathology in Rats with Chronic Spinal Cord Injury.

Journal: Stem cell reports

Published: January 31, 2017

Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease.

Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease.

Journal: Molecular therapy. Methods & clinical development

Published: January 20, 2017

Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice.

Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice.

Journal: BBA clinical

Published: January 06, 2017

Relative distribution of Gb3 isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry.

Relative distribution of Gb3 isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry.

Journal: Bioanalysis

Published: August 16, 2016

Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.

Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.

Journal: The American journal of pathology

Published: August 09, 2016

Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.

Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: July 07, 2016

Markedly perturbed hematopoiesis in acid ceramidase deficient mice.

Markedly perturbed hematopoiesis in acid ceramidase deficient mice.

Journal: Haematologica

Published: February 16, 2015

Direct genesis of functional rodent and human schwann cells from skin mesenchymal precursors.

Direct genesis of functional rodent and human schwann cells from skin mesenchymal precursors.

Journal: Stem cell reports

Published: October 17, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026